Xilis

Xilis is attempting to revolutionize cancer treatment through its MicroOrganoSphere (MOS) technology. The company’s tech uses a cancer patient’s tissue sample to recreate thousands of replica models of their tumors, which are then tested against multiple treatments and drugs to find the most effective option.

• Mission focused – Build for everyone, with everyone. At Xilis, we have an unwavering commitment to use our technology, skills, and time to provide patients with transformative new diagnostics and therapeutics. The Xilis team is mission driven by keeping patients and products in mind when making decisions, building for everyone, and connecting with our community.
• Data-driven decision making – Integrity breeds integrity, trust breeds trust. At Xilis, we strive to become a trusted component of our healthcare industry. Our actions, decisions, and behaviors have an impact on the quality of the work we do, the value of our products to patients, and ultimately on the impact we have on the community. Data, and the integrity that stems from it, needs to guide our every action so we can precisely assess any given situation and make decisions that will most benefit patients.
• Servant leadership – Cross-functional support and leadership. Xilis is first and foremost at the service of patients and dedicated to bringing novel and life saving diagnostic assays and drug treatments to patients. We firmly believe the legitimacy of authority in managerial relationships comes from empowering and enabling the right people to perform the most important and valuable tasks and make the right decisions. The leadership and management of Xilis are singularly dedicated to our team's success by committing to serve and build trust within our organization and with our partners.
• Team first – Cross-functional by nature. As a TechBio company, Xilis requires a vast breadth of professionals with extremely diverse skill sets working in harmony to deliver on the potential of its technology and reach transformative impact by developing complex, high-performance products for patients. This environment requires a significant amount of humility and effort to actively engage with partners who have dramatically different work experiences, needs, vernacular, and expertises - all critical to the success of our common endeavor. At Xilis, we go above and beyond to ensure company-wide cohesion and cross-functional collaboration as we recognize we cannot make progress alone.

Total funding: $92m